Eledon Pharmaceuticals to be Acquired by Medicxi Affiliate

TL;DR

Eledon Pharmaceuticals is getting bought by Medicxi Ventures, deal expected to close Q1 2025.

AI Summary

Eledon Pharmaceuticals, Inc. announced on October 29, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Medicxi Ventures. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. Eledon Pharmaceuticals, Inc. was formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.

Why It Matters

This acquisition by a venture capital firm suggests a strategic shift or validation of Eledon's pipeline, potentially impacting its future development and shareholder value.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and the terms of the deal, while definitive, may still present integration or regulatory risks.

Key Players & Entities

• Eledon Pharmaceuticals, Inc. (company) — Registrant
• Medicxi Ventures (company) — Acquiring entity's affiliate
• Novus Therapeutics, Inc. (company) — Former name of Registrant
• Tokai Pharmaceuticals Inc (company) — Former name of Registrant
• October 29, 2024 (date) — Date of Report
• First quarter of 2025 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market

Filing Documents

• eldn-20241029.htm (8-K) — 40KB
• eldn-ex99_1.htm (EX-99.1) — 26KB
• img20068692_0.jpg (GRAPHIC) — 7KB
• 0000950170-24-117946.txt ( ) — 195KB
• eldn-20241029.xsd (EX-101.SCH) — 24KB
• eldn-20241029_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 29, 2024, Eledon Pharmaceuticals Inc. (the "Company") issued a press release announcing initial data from subjects with type 1 diabetes treated with tegoprubart, the Company's investigational anti-CD40L antibody, as part of an immunosuppression regimen following islet transplantation in an investigator-initiated trial at the University of Chicago Medicine's Transplantation Institute. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Also, on October 29, 2024, the Company updated its investor presentation, which is posted on the Company's website at https://ir.eledon.com/news-and-events/publications-and-presentations . The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the "Securities Act"), unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Eledon Pharmaceuticals, Inc. Date: October 29, 2024 By: /s/ David-Alexandre C. Gros, M.D. Name: David-Alexandre C. Gros, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR